A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease

A phase-I study was conducted to determine the safety, pharmacokinetics, and activity of combination 2',3'-dideoxyinosine (ddI) and ribavirin against HIV-1-positive individuals with CD4+ cell counts less than or equal to 500/mul.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of acquired immune deficiency syndromes (1999) 1996-11, Vol.13 (3), p.235-246
Hauptverfasser:	JAPOUR, A. J, LERTORA, J. J, COONEY, E, POLLARD, R, TIMPONE, J, MCLAREN, C, JOHANNESON, N, WOOD, K, BOOTH, D. K, BASSIAKOS, Y, CRUMPACKER, C. S, MEEHAN, P. M, ERICE, A, CONNOR, J. D, GRIFFITH, B. P, CLAX, P. A, HOLDEN-WILTSE, J, HUSSEY, S, WALESKY, M
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Biological and medical sciences Drug therapy HIV Human immunodeficiency virus human immunodeficiency virus 1 Medical sciences Pharmacology. Drug treatments
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A phase-I study was conducted to determine the safety, pharmacokinetics, and activity of combination 2',3'-dideoxyinosine (ddI) and ribavirin against HIV-1-positive individuals with CD4+ cell counts less than or equal to 500/mul.
ISSN:	1077-9450 1525-4135 2331-6993 1944-7884
DOI:	10.1097/00042560-199611010-00005